Teva CEO to Outline Growth Strategy at Goldman Sachs Healthcare Conference
Event summary
- Teva CEO Richard Francis to participate in a fireside chat on June 8, 2026, at 8:00 AM ET.
- Webcast available live and archived for 30 days on Teva’s Investor Relations website.
- Teva positioning itself as a leading innovative biopharmaceutical company, supported by generics business.
- Forward-looking statements include financial guidance and strategic plans, subject to market risks.
The big picture
Teva’s participation in the Goldman Sachs Global Healthcare Conference underscores its strategic shift toward innovation, aiming to compete in the biopharmaceutical space while managing its substantial generics portfolio. The company’s ability to execute its Pivot to Growth strategy will be critical amid increasing competition and regulatory challenges in the pharmaceutical industry.
What we're watching
- Execution Risk
- How Teva will balance its Pivot to Growth strategy with existing debt and market competition.
- Market Positioning
- Whether Teva can successfully transition from generics to innovative biopharmaceuticals.
- Financial Performance
- The pace at which Teva achieves expected cost savings and financial targets.
Related topics